Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,629.29
(
0.07%
)
US TECH 100
23,689.20
(
-0.45%
)
Dow Jones
46,216.47
(
-0.02%
)
Brent Oil
101.48
(
-4.79%
)
Bitcoin
70,355.93
(
-1.25%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 165681

Saturday, 01/25/2014 1:17:18 PM

Saturday, January 25, 2014 1:17:18 PM

Post# of 257259
CHMP approves GSK’s weekly GLP-1, Eperzan (a/k/a albiglutide):

http://finance.yahoo.com/news/eu-regulator-backs-bayer-gsk-124116415.html

The PDUFA date for the US NDA is 4/15/14 due to a 30-month delay (http://www.gsk.com/media/press-releases/2013/regulatory-update--albiglutide-us-pdufa-date-extended-by-three-m.html ).

The GLP-1 market is pretty crowded already.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now